Once-Yearly Reclast(R)* Demonstrates Highly Significant Fracture Risk Reductions in the Treatment of Postmenopausal (PR Newswire via Yahoo! Finance)
New Phase III data presented for the first time demonstrated that the investigational treatment Reclast ^ 5 mg was highly effective in reducing the incidence of bone fracture in women with postmenopausal osteoporosis across the most common fracture sites -- hip, spine and non-spine^^ -- with sustained effect over three years.

Molecular Biomarkers Predicting Efficacy of Introgen Therapeutics' ADVEXIN Cancer Therapy are Highlighted at Major (FinanzNachrichten)
CHICAGO, Sept. 15 /PRNewswire-FirstCall/ -- News of Introgen Therapeutics, ( Nachrichten ) Inc.'s use of a molecular biomarker to predict the efficacy of its ADVEXIN cancer therapy was released yesterday by the American Association for Cancer Research (AACR). Introgen has reached agreement with the U.S. Food and Drug Administration (FDA) to incorporate the use of Introgen's p53 molecular